Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia

  • Oh, Hyun Jin (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Cho, Mun Sung (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Lee, Jae Wook (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Jang, Pil-Sang (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Chung, Nack-Gyun (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Cho, Bin (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Kim, Hack-Ki (Department of Pediatrics, The Catholic University of Korea College of Medicine)
  • Received : 2012.09.15
  • Accepted : 2012.10.25
  • Published : 2013.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Despite the established role of imatinib (IM) in chronic myelogenous leukemia (CML) in adults, there are few reports on its efficacy in children. In this study, we compared the outcomes of children with CML before and after the advent of IM-based treatment. Methods: The study cohort consisted of 52 patients treated for CML at the Department of Pediatrics, The Catholic University of Korea from January 1995 to October 2010. Patients were divided and analyzed according to the preImatinib group (pre-IMG) and imatinib group (IMG). Results: Median age at diagnosis for the overall cohort (pre-IMG, n=27; IMG, n=25) was 9 years, with a median follow-up duration of survivors of 84 months. Except for 5 patients in the IMG, all were diagnosed in chronic phase (CP). The overall survival (OS) of patients diagnosed in CP was 45.7% and 89.7% for pre-IMG and IMG, respectively (P=0.025). The OS of hematopoietic stem cell transplantation (HSCT) recipients in the 2 groups was similar, but the OS of patients diagnosed in CP who did not receive HSCT was superior in IMG (91.7% vs. 16.7%, P=0.014). Of the 12 patients in IMG who remained on IM without HSCT, 2 showed disease progression, compared to 11 of 12 in pre-IMG. No difference was observed in the progression free survival (PFS) of matched donor HSCT recipients and IM-based treatment recipients. Conclusion: Similar PFS of patients treated with IM and those who received matched donor HSCT underscore the potential of IM as effective first-line treatment in childhood CML.

Keywords

References

  1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340: 1330-40. https://doi.org/10.1056/NEJM199904293401706
  2. Altman AJ. Chronic leukemias of childhood. Pediatr Clin North Am 1988;35:765-87. https://doi.org/10.1016/S0031-3955(16)36509-9
  3. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517-36.
  4. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17. https://doi.org/10.1056/NEJMoa062867
  5. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23:1054-61. https://doi.org/10.1038/leu.2009.38
  6. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35. https://doi.org/10.1016/S1470-2045(10)70233-3
  7. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123-9. https://doi.org/10.1182/blood-2011-08-376087
  8. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841-51. https://doi.org/10.1016/S1470-2045(11)70201-7
  9. Lakshmaiah KC, Bhise R, Purohit S, Abraham LJ, Lokanatha D, Suresh TM, et al. Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate. Leuk Lymphoma 2012;53:2430-3. https://doi.org/10.3109/10428194.2012.694076
  10. Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 2011;29:2827-32. https://doi.org/10.1200/JCO.2010.32.7114
  11. Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Bekassy AN, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006;20:187-92. https://doi.org/10.1038/sj.leu.2404051
  12. Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood 2012;119:1821-30. https://doi.org/10.1182/blood-2011-10-380774
  13. Aplenc R, Blaney SM, Strauss LC, Balis FM, Shusterman S, Ingle AM, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J Clin Oncol 2011;29:839-44. https://doi.org/10.1200/JCO.2010.30.7231
  14. Vardiman JW, Melo JV, Baccarani M, Thiele J. Chronic myelogenous leukemia, BCR-ABL 1 positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC, 2008:32-7.
  15. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51. https://doi.org/10.1200/JCO.2009.25.0779
  16. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Ver. 4.0 [Internet]. Bethesda: National Cancer Institute; [cited 2012 Jul 25]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf.
  17. Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003;102:1224-31. https://doi.org/10.1182/blood-2002-12-3637
  18. Millot F, Esperou H, Bordigoni P, Dalle JH, Michallet M, Michel G, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2003;32:993-9. https://doi.org/10.1038/sj.bmt.1704255
  19. Muramatsu H, Takahashi Y, Sakaguchi H, Shimada A, Nishio N, Hama A, et al. Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era. Int J Hematol 2011;93:186-91. https://doi.org/10.1007/s12185-010-0764-9
  20. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): Colon/rectal cancer. ver. 1. 2010 [Internet]. Fort Wathington: NCCN; c2012 [cited 2012 Aug 27]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  21. Lee JW, Chung NG. The treatment of pediatric chronic myelogenous leukemia in the imatinib era. Korean J Pediatr 2011;54:111-6. https://doi.org/10.3345/kjp.2011.54.3.111
  22. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022-8. https://doi.org/10.1182/blood-2007-10-116475
  23. Koren-Michowitz M, Volchek Y, Naparstek E, Gavish I, Levi I, Rowe JM, et al. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol 2012;30:200-5. https://doi.org/10.1002/hon.2005
  24. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-9. https://doi.org/10.1182/blood-2006-07-036012
  25. DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, et al. Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004;10:5065-71. https://doi.org/10.1158/1078-0432.CCR-03-0580
  26. Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL, et al. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010;16:639-46. https://doi.org/10.1016/j.bbmt.2009.11.026
  27. Bansal D, Shava U, Varma N, Trehan A, Marwaha RK. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer 2012;59:481-4. https://doi.org/10.1002/pbc.23389
  28. Shima H, Tokuyama M, Tanizawa A, Tono C, Hamamoto K, Muramatsu H, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011;159:676-81. https://doi.org/10.1016/j.jpeds.2011.03.046

Cited by

  1. Leucémie myéloïde chronique des sujets jeunes : expérience dans une unité d’hématologie clinique au Sénégal vol.3, pp.4, 2013, https://doi.org/10.1016/j.oncohp.2015.10.003
  2. Optimal management for pediatric chronic myeloid leukemia vol.58, pp.3, 2013, https://doi.org/10.1111/ped.12876